Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Canada's Xenon Pharma's depression drug fails to meet main goal in study
07:43am, Monday, 27'th Nov 2023
Canada's Xenon Pharmaceuticals said on Monday that its experimental drug to treat moderate to severe major depressive disorder (MDD) had failed to significantly reduce the severity of depressive episo
Xenon Pharmaceuticals: XEN1101 Remains A Gem Despite The Dip
04:55am, Sunday, 26'th Nov 2023
XEN1101 shows clinical promise in epilepsy and MDD, with Phase 3 trials critical for its broader efficacy evaluation. Financially, Xenon faces a stark YOY revenue drop and rising R&D costs but maintai
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2023 Financial Results and Provide Corporate Update
04:01pm, Wednesday, 01'st Nov 2023
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter
Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
08:30am, Friday, 06'th Oct 2023
VANCOUVER, British Columbia, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
Xenon Pharmaceuticals to Present at TD Cowen's 3rd Annual Novel Mechanisms in Neuropsychiatry Summit
04:01pm, Thursday, 14'th Sep 2023
VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present a
Polarean Imaging partners up to enhance potential of Xenon 129 MRI technology
02:46am, Friday, 08'th Sep 2023
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) (AIM: POLX), a specialist in advanced magnetic resonance imaging (MRI) for the lungs, has announced a strategic partnership with VIDA Diagnostics, a clinical
Xenon Pharmaceuticals to Present at the Wells Fargo 2023 Healthcare Conference
04:01pm, Thursday, 31'st Aug 2023
VANCOUVER, British Columbia, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
Xenon Is Well-Funded Heading Into Key Readouts
09:20am, Sunday, 13'th Aug 2023
Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health is commendable, but widening net losses and escalat
Wall Street Analysts Believe Xenon Pharmaceuticals (XENE) Could Rally 36.75%: Here's is How to Trade
11:32am, Friday, 11'th Aug 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionab
Xenon Pharmaceuticals Inc. (XENE) Q2 2023 Earnings Call Transcript
11:27pm, Wednesday, 09'th Aug 2023
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr.
Xenon Pharmaceuticals (XENE) Reports Q2 Loss, Misses Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Xenon Pharmaceuticals (XENE) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.55 per share a year ago.
Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
04:35pm, Tuesday, 06'th Jun 2023
VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
Xenon Pharmaceuticals: Navigating The Neural Network Of Epilepsy And Depression
11:26am, Tuesday, 23'rd May 2023
In Q1 2023, Xenon had $687.3 million in cash and marketable securities, down from $720.8 million in Q4 2022. They anticipate sufficient funding for operations until 2026. XEN1101, a leading candidate
Xenon Pharmaceuticals Inc. (XENE) Q1 2023 Earnings Call Transcript
07:13pm, Saturday, 13'th May 2023
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Sherry Aulin - CFO Ian Mortimer - President and CEO Dr. Chris Kenney - CMO Dr. Chr
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
04:01pm, Thursday, 11'th May 2023
VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at
